Close Menu
  • Magazine
    • Current Issue
    • Issue Archive
    • Subscribe
  • Topics
    • AI/Machine Learning
    • CT
    • Fluoroscopy/C-Arm
    • General Radiology
    • Interventional Radiology
    • MRI
    • Nuclear Medicine/Molecular Imaging
    • PACS/RIS/Informatics
    • Radiation Oncology
    • Radiology Management
    • Reimbursement & Coding
    • Research News
    • Ultrasound
    • Women’s Imaging
  • E-Newsletter
  • Education
    • ARMRIT Annual Meeting
    • MRI Books
    • Webinars
  • Careers
  • Events
  • Resources
    • Product Directories
    • Resource Listing
    • Reprints
    • Writers’ Guidelines

Join Our Email List

Facebook X (Twitter) LinkedIn
Trending
  • Sharper Imaging
  • Declaration of Independence?
  • In the Mix
  • Screen Test
  • Editor’s Note: Thinking Ahead
  • Pediatric Imaging: Access for All Ages
  • Managing to Succeed: Beating Burnout
  • On the Case
Wednesday, November 18
  • About
  • Contact
  • Advertise
  • Gift Shop
Facebook X (Twitter) LinkedIn
Radiology Today MagazineRadiology Today Magazine
Subscribe
  • Magazine
    • Current Issue
    • Issue Archive
    • Subscribe
  • Topics
    • AI/Machine Learning
    • CT
    • Fluoroscopy/C-Arm
    • General Radiology
    • Interventional Radiology
    • MRI
    • Nuclear Medicine/Molecular Imaging
    • PACS/RIS/Informatics
    • Radiation Oncology
    • Radiology Management
    • Reimbursement & Coding
    • Research News
    • Ultrasound
    • Women’s Imaging
  • E-Newsletter
  • Education
    • ARMRIT Annual Meeting
    • MRI Books
    • Webinars
  • Careers
  • Events
  • Resources
    • Product Directories
    • Resource Listing
    • Reprints
    • Writers’ Guidelines
Radiology Today MagazineRadiology Today Magazine
Home » Sharper Imaging
CT

Sharper Imaging

Vol. 27 No. 6 P. 12Keith LoriaNovember 18, 202611 Mins Read
Facebook Twitter LinkedIn Email Threads Bluesky Copy Link

Photon-counting CT is moving into routine care, where its value willbe measured by how oftenits data changes diagnosis,treatment, and workflow.

Photon-counting CT (PCCT) has reached the point where better-looking images are no longer enough. “We try not to look at whether it is more bits, more bytes, or thinner slices,” says Matthew Fuld, PhD, director of PCCT at Siemens Healthineers North America. “The question is: What is the clinical change? How do you change patient outcomes with a technology such as photon counting?”

That question has become more pressing as the technology moves beyond a small group of research systems. Siemens Healthineers introduced the first clinically available full-body PCCT system in 2021 and has since expanded NAEOTOM into a three-scanner class.

GE HealthCare’s Photonova Spectra received FDA clearance in March 2026 and CE Mark in August 2026. Canon Medical has introduced photon-counting technology on a clinical CT platform, while Philips is advancing its spectral PCCT through clinical research.

The detectors distinguish these systems from conventional energy-integrating CT. Rather than first converting X-rays into visible light and then an electrical signal, a photon-counting detector converts each X-ray photon directly into an electrical signal and measures its energy. The resulting data can support thinner slices, higher spatial resolution, spectral analysis, noise reduction, and lower-dose imaging. Whether those capabilities matter, however, depends on the examination, patient, protocol, and decisions that follow.

Detector materials and designs differ by manufacturer. For example, GE’s Deep Silicon architecture sorts the signal into eight energy bins, while Canon’s system uses cadmium zinc telluride detectors developed with Redlen Technologies. The energy information can be reconstructed into material maps that help distinguish iodine, calcium, fat, and water. Because spectral data are acquired with the examination rather than selected only through a special dual-energy protocol, radiologists can return to the data when an unexpected question arises.

Routine Care Takes Shape

Northwestern Medicine offers a view of what a mature clinical deployment can look like. The health system has three NAEOTOM scanners, with two serving inpatients and one at an outpatient imaging center. All three are being used to full clinical capacity, according to Amir A. Borhani, MD, FSAR, a professor of radiology and surgery at Northwestern University Feinberg School of Medicine and medical director of CT at Northwestern Memorial Hospital in Chicago. “We use them for a variety of clinical indications, evenly distributed between abdominal, cardiac, chest, and neuro indications,” Borhani says.

“We have a list of indications where patients benefit most from this technology and try our best to schedule those patients to one of our photon-counting CT scanners.”

Those indications include coronary CT angiography, liver and pancreatic imaging, rectal cancer imaging, and examinations before and after transplantation. Northwestern also directs pediatric and pregnant patients to the scanners, when appropriate, to take advantage of lower radiation doses.

Clinical volume is dispelling the idea that photon counting belongs only in highly controlled research settings. “We have sites in the United States performing 100 patient examinations a day, and I’ve seen sites in China do more than 170 examinations a day across a wide mix of clinical fields,” Fuld says.

Reading more and thinner images does not necessarily mean a longer interpretation. Fuld notes radiologists often request thinner slices and sharper reconstructions because seeing the pathology more clearly can reduce the time spent moving between images or debating an equivocal finding.

“The potential for much higher spatial resolution, lower radiation dose, spectral information, and higher contrast gives physicians a lot of tools,” he says. “If you can see the underlying pathology better, you can actually interpret it faster.”

The gains are not confined to one subspecialty. Fuld points to improved visualization in oncology, neurology, musculoskeletal imaging, and cardiology. He also cites the detection of difficult-to-find cerebrospinal fluid venous fistulas as an example of high resolution changing a patient’s path. Patients with such leaks may undergo years of imaging before the source is identified.

“Photon-counting CT has been shown to be a reliable way to detect CSF venous fistulas,” Fuld says. “Once the neuroradiologist finds the leak, it can be treated. At institutions pioneering this work, photon counting is helping these patients receive much better treatment.”

Cardiac Imaging Leads

Cardiac CT is emerging as one of the clearest early use cases because several advantages of photon counting converge in the same examination. High spatial resolution helps evaluate small vessels and stents, improved temporal resolution on dual-source systems limits motion, and spectral data can help separate calcium and contrast.

At the University of Wisconsin– Madison, Giuseppe Toia, MD, MS, and colleagues have evaluated GE’s silicon-based photon-counting technology across neuro, cardiovascular, thoracic, abdominal, and musculoskeletal imaging. Toia is an associate professor of radiology and medical physics, chief of abdominal imaging and intervention, and CT modality chief at the University of Wisconsin School of Medicine and Public Health. The group is currently completing physics validation and calibration before opening the FDA-cleared Photonova Spectra to a clinical schedule.

Toia says coronary disease offers a direct example of additional detail influencing management. Calcium can bloom on conventional CT, making it difficult to determine where calcified plaque ends and the vessel lumen begins. In UW’s evaluation, the combination of higher contrast-to-noise ratio and lower noise reduced that effect and improved assessment of intraluminal stenosis.

“There have been at least two examples where, if the patients had only undergone energy-integrating detector CT, we may have overcalled or undercalled the degree of plaque burden within their coronary arteries,” Toia says. “That changes the trajectory of a patient’s follow-up plan, whether they need medication, watchful waiting, or potentially a referral to interventional cardiology.”

Fuld sees a similar role for coronary CTA in deciding which patients need medical therapy and which should proceed to the catheterization lab. He believes the next advance will move beyond measuring the degree of obstruction to characterizing plaque composition.

Philips is also concentrating research on the coronary care pathway. The company coordinates COMBINE-CT, a European project that has advanced to clinical validation and includes studies of spectral PCCT for assessing bypass grafts and previously implanted stents.

“Cardiovascular imaging is one of several areas of this work,” says Dan Xu, business leader of CT at Philips. “As this work progresses, Philips is focused on demonstrating that additional information can meaningfully improve clinical decision-making and fit the workflow realities of routine care.”

Transplant and Oncology Applications

Abdominal imaging presents both compelling cases and harder questions about measurable value. Northwestern has made PCCT its modality of choice after liver transplantation. Borhani says the system’s ultrahigh-resolution mode provides a better view of allograft arteries and surgical anastomoses.

“We frequently see discrepancy between conventional CTA and high-resolution photon-counting CTA in the assessment of arterial anastomoses after liver transplantation,” Borhani says. “Photon counting allows more accurate assessment of the true size and configuration of the anastomosis, which increases the radiologist’s accuracy and confidence.”

In a Northwestern cohort that underwent both photon-counting CTA and conventional angiography, Borhani says the two methods showed very high agreement. Conventional angiography is considered the reference standard. The use of PCCT reduced false-positive diagnoses of strictures and, consequently, the number of unnecessary angiograms.

Toia describes another potential advantage in a patient who had undergone microwave ablation of a liver tumor. Posttreatment hemorrhage and protein can raise conventional CT numbers, complicating the assessment of whether viable tumor remains. The UW team combined low-energy monoenergetic images with iodine maps to examine the ablation zone.

“By using an iodine concentration on top of the CT number, we can be more confident that ablation zones with no iodine content truly have no residual disease,” Toia says. “It was helpful for us to be confident that we were doing the clinical job we set out to do.”

GE is evaluating similar combinations of high-definition, low-kiloelectronvolt images and material maps for abdominal oncology. Chad Rowland, executive director of global CT at GE HealthCare, says the aim is to improve soft-tissue contrast and lesion characterization rather than merely generate a sharper image.

“The goal is to give clinicians additional information that can support detection, characterization, and monitoring,” Rowland says. “Depending on the clinical question, that could have implications for lesion detection and delineation, staging, treatment planning, or follow-up.”

Workflow Is the Test

Greater detail means significantly more data. Toia estimates that a photon-counting study can generate approximately 20 times as much data as a conventional CT examination. Thinner slices and multiple energy datasets increase reconstruction demands, network traffic, storage requirements, and the number of images available to review.

The answer is not to activate every feature for every patient. A pancreatic mass protocol may justify ultrahigh spatial resolution because the radiologist needs to evaluate subtle disease along vessels near the pancreas. A routine abdomen and pelvis examination for nonspecific pain may not warrant the same reconstruction burden.

“You have to balance the clinical value with the technological advantage,” Toia says. “You need a CT champion and a team partnering with the vendor to make sure those protocols are optimized.”

Radiation dose requires the same clinical judgment. Challenging examinations involving larger patients, motion, or arms that cannot be raised may yield diagnostic images at a dose that previously would have required an increase. Routine examinations may offer an opportunity to lower dose while maintaining image quality.

Vendors are trying to keep the added spectral and spatial information from complicating acquisition. GE designed Photonova Spectra around a universal full-fidelity scan approach, accelerated reconstruction, and an operator environment intended to reduce exam-specific setup. Siemens uses a common operating environment, visualization tools, automation, and AI across its photon-counting and conventional CT platforms.

“Photon-counting CT should give clinicians more information without asking them to manage more complexity,” Rowland says.

Cost remains another constraint, particularly for facilities with modest volume. Fuld says the choice depends on the patient mix, throughput, and whether a department has clinical champions prepared to redesign protocols rather than run the scanner like a conventional system. Siemens’ addition of dual-source and single-source models is intended to widen the range of settings that can adopt the technology.

Building the Next Detector

Development is continuing at both the system and material levels. Philips is building on its detector-based spectral CT experience while studying ultrahigh spatial resolution and simultaneous spectral information for visualizing small structures, characterizing tissue, differentiating materials, and reducing calcium and metal artifacts.

“Philips is advancing the technology through clinical research and collaborations with academic and health care partners,” Xu says. “The goal is to build the evidence on clinical value, workflow fit, and economics needed to support future mainstream adoption.”

Researchers from the University of Victoria in British Columbia, Canada, and Redlen Technologies are looking even deeper into the detector. Using the Canadian Light Source at the University of Saskatchewan in Canada, they studied an oxide contact layer only a few atoms thick that controls the extraction of electrons from a cadmium zinc telluride detector. The team is evaluating a sulfide as an alternative contact material. Improving that interface could make detectors more sensitive and better able to distinguish tissues with similar densities.

“If you can detect a small thing such as a growth that looks the same as surrounding tissue, you won’t have to wait until it gets big to see it on a CT scan,” says Tom Tiedje, professor emeritus in electrical engineering at the University of Victoria and the University of British Columbia. “That is definitely an advantage.”

Another long-range goal is to move beyond today’s typical focus on a single iodinated contrast agent. Multiple energy thresholds could allow a scan to distinguish two or more agents, potentially providing different kinds of physiologic or tissue information in one examination. Fuld says current systems can collect the necessary energy-resolved data, but clinical use will depend on the development and regulatory approval of new contrast materials. That makes the future of photon counting partly a pharmaceutical question, rather than solely an engineering one.

Beyond Better Images

The longer-term possibilities include multiple contrast agents, quantitative tissue characterization, spectral biomarkers, earlier cancer detection, and closer assessment of treatment response. Musculoskeletal imaging may benefit from clearer visualization of nondisplaced fractures and the bone surrounding metal hardware. Lung imaging could use fine texture patterns to monitor fibrosis and other interstitial disease.

Each possibility raises the same question posed at the start: Does the additional information alter care enough to justify the equipment, data, and workflow? GE’s Rowland says continued collaborations are essential for establishing which applications produce value in everyday settings. Philips is focusing on clinical validation and economics as well as technical performance. Northwestern’s transplant experience already suggests that a targeted protocol can eliminate unnecessary invasive testing.

Toia believes cardiac imaging will advance quickly because the relationship between better resolution and the clinical question is readily apparent. Abdominal imaging will require longer studies that connect clearer lesions with staging, treatment selection, and outcomes.

“Yes, we are getting better images, and that makes radiologists more confident in what they are looking at,” Toia says. “But does that translate to a difference in care? There needs to be more data collection on that.”

Keith Loria is a freelance writer based in Oakton, Virginia. He is a frequent contributor to Radiology Today.

Feature
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Posts

Declaration of Independence?

November 18, 2026

In the Mix

November 18, 2026

Screen Test

November 18, 2026
  • Facebook
  • X
  • LinkedIn

E-Newsletters

A trusted resource for industry professionals, Radiology Today reports the latest news and information that matters to radiologists, radiology administrators, and technologists.

1721 Valley Forge Road #486, Valley Forge, PA 19481
Phone: 800-278-4400 or 610-948-9500
Subscriptions: 833-790-6897

Facebook X (Twitter) LinkedIn

Subscribe

  • Home
  • Subscribe
  • About
  • Contact
  • Advertise
  • Privacy Policy
  • Terms & Conditions
© 2026 Radiology Today Magazine. All rights reserved.

Type above and press Enter to search. Press Esc to cancel.